Moderna looks ready to take on the world, with the efficacy of its new cancer vaccine turning heads.
Vaccine stocks spiral as their efficacy against the Delta variant is called into question. Moderna takes the worst of it, down just under 16% to close at $385.33.
Vaccine hero Moderna opens Monday up 6% and finishes the day with a 9.5% bump, building on its share price jump of 10% on Friday on news that the biotech leader is set to get a S&P 500 listing.
See all events